NAT2
Arylamine N-acetyltransferase 2
Protein Summary
Participates in the detoxification of a plethora of hydrazine and arylamine drugs. Catalyzes the N- or O-acetylation of various arylamine and heterocyclic amine substrates and is able to bioactivate several known carcinogens. This gene encodes an enzyme that functions to both activate and deactivate arylamine and hydrazine drugs and carcinogens. Polymorphisms in this gene are responsible for the N-acetylation polymorphism in which human populations segregate into rapid, intermediate, and slow acetylator phenotypes. Polymorphisms in this gene are also associated with higher incidences of cancer and drug toxicity. A second arylamine N-acetyltransferase gene (NAT1) is located near this gene (NAT2). [provided by RefSeq, Jul 2008]
- ENST00000286479
- ENSP00000286479
- ENSG00000156006
- AAC2
- AAC2
- PNAT
- NAT-2
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
biological term | 0.98 | ||
chemical | 0.91 | ||
disease | 0.7 | ||
gene perturbation | 0.63 | ||
transcription factor perturbation | 0.54 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 779.74 (req: < 5)
Gene RIFs: 438 (req: <= 3)
Antibodies: 243 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 779.74 (req: >= 5)
Gene RIFs: 438 (req: > 3)
Antibodies: 243 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 2
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0